Haupt Pharma AG
Haupt Pharma AG, a leading contract development and manufacturing organisation (CDMO), is headquartered in Germany and operates extensively across Europe. Founded in 1994, the company has established itself as a key player in the pharmaceutical industry, specialising in the development and production of solid dosage forms, sterile products, and complex formulations. With a commitment to quality and innovation, Haupt Pharma AG offers a comprehensive range of services, including formulation development, analytical services, and regulatory support. Their state-of-the-art facilities and adherence to stringent quality standards set them apart in the competitive landscape. Recognised for their expertise and reliability, Haupt Pharma AG has achieved significant milestones, including successful partnerships with major pharmaceutical companies. Their dedication to excellence positions them as a trusted partner in the global healthcare market.
DitchCarbon Score
How does Haupt Pharma AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Haupt Pharma AG's score of 14 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Haupt Pharma AG's reported carbon emissions
In 2023, Haupt Pharma AG reported significant carbon emissions, totalling approximately 7,507,900,000 kg CO2e across all scopes. This includes about 24,079,000 kg CO2e from Scope 1 emissions and approximately 1,190,000 kg CO2e from Scope 2 emissions. The company also disclosed substantial Scope 3 emissions, which accounted for about 7,483,631,000 kg CO2e, with notable contributions from purchased goods and services (approximately 1,036,971,000 kg CO2e) and upstream transportation and distribution (about 86,338,000 kg CO2e). Comparatively, in 2022, Haupt Pharma AG's emissions were approximately 24,991,000 kg CO2e for Scope 1 and about 9,937,000 kg CO2e for Scope 2, indicating a slight reduction in Scope 1 emissions in 2023. The company has not publicly committed to specific reduction targets or initiatives, nor does it appear to have set Science-Based Targets Initiative (SBTi) reduction targets. Haupt Pharma AG's emissions intensity for Scope 1 and 2 combined was reported at 0.0081 t per million euros in revenue for 2022, improving to 0.0055 t per million euros in 2023, reflecting a positive trend in emissions efficiency. The absence of formal reduction commitments highlights an opportunity for the company to enhance its climate strategy and align with industry standards for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 24,991,000 | 00,000,000 |
| Scope 2 | 9,937,000 | 0,000,000 |
| Scope 3 | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Haupt Pharma AG is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
